J&J, Leg­end say Carvyk­ti beat stan­dard ther­a­py in ear­li­er-line blood can­cer

J&J and Leg­end Biotech’s next step in turn­ing their CAR-T ther­a­py Carvyk­ti in­to a po­ten­tial megablock­buster has suc­ceed­ed, the com­pa­nies said Fri­day.

Carvyk­ti achieved the pri­ma­ry end­point — pro­gres­sion-free sur­vival — in an open-la­bel Phase III study test­ing the treat­ment in sec­ond- to fourth-line mul­ti­ple myelo­ma pa­tients. The CAR­TI­TUDE-4 tri­al, for which there aren’t any hard da­ta yet, rep­re­sents the biggest de­vel­op­ment for Carvyk­ti’s abil­i­ty to com­pete with Bris­tol My­ers Squibb’s Abec­ma since its ap­proval last Feb­ru­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER